CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2023—BioMérieux announced it has received the CE mark for its Vidas TBI (GFAP, UCH-L1), a test to support the assessment of patients who have mild traumatic brain injury. The blood test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1), two brain biomarkers that are released into the bloodstream during the first hour following a brain injury. It aims to fill a gap in patient screening methods by ruling out acute intracranial lesions and helping to determine if a CT scan is necessary.
Vidas TBI has a testing window of up to 12 hours and can be run on Vidas 3 and Vidas Kube immunoassay analyzers. Commercial launch of the test is planned in selected European, North African, and South American markets in the last quarter of this year and in 2024–2025 for the rest of the world.
BioMérieux, +33 (0)4 78 87 20 00